CA3094476C - HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR CANCER TREATMENT - Google Patents

HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR CANCER TREATMENT

Info

Publication number
CA3094476C
CA3094476C CA3094476A CA3094476A CA3094476C CA 3094476 C CA3094476 C CA 3094476C CA 3094476 A CA3094476 A CA 3094476A CA 3094476 A CA3094476 A CA 3094476A CA 3094476 C CA3094476 C CA 3094476C
Authority
CA
Canada
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3094476A
Other languages
English (en)
French (fr)
Other versions
CA3094476A1 (en
Inventor
Zenon D. Konteatis
Mingzong Li
Peng Liu
Matthew Medeiros
Samuel K. Reznik
Zhihua Sui
Jeremy M. Travins
Shubao Zhou
Guangning Ma
Janeta Popovici-Muller
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CA3094476A1 publication Critical patent/CA3094476A1/en
Application granted granted Critical
Publication of CA3094476C publication Critical patent/CA3094476C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3094476A 2018-03-30 2019-03-28 HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR CANCER TREATMENT Active CA3094476C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
CNPCT/CN2018/081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (2)

Publication Number Publication Date
CA3094476A1 CA3094476A1 (en) 2019-10-03
CA3094476C true CA3094476C (en) 2025-05-06

Family

ID=67439309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3094476A Active CA3094476C (en) 2018-03-30 2019-03-28 HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR CANCER TREATMENT

Country Status (21)

Country Link
US (1) US11524960B2 (enExample)
EP (1) EP3774805B1 (enExample)
JP (2) JP7350005B2 (enExample)
KR (1) KR102736073B1 (enExample)
CN (1) CN111936499B (enExample)
AR (1) AR115326A1 (enExample)
AU (1) AU2019243289B2 (enExample)
BR (1) BR112020020104A2 (enExample)
CA (1) CA3094476C (enExample)
EA (1) EA202092320A1 (enExample)
ES (1) ES2973114T3 (enExample)
HU (1) HUE066282T2 (enExample)
IL (1) IL277665B2 (enExample)
MA (1) MA52232A (enExample)
MX (1) MX2020010005A (enExample)
PH (1) PH12020551507A1 (enExample)
PL (1) PL3774805T3 (enExample)
SG (1) SG11202009195WA (enExample)
TW (1) TWI719437B (enExample)
UA (1) UA127059C2 (enExample)
WO (1) WO2019191470A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006841A (es) 2018-12-10 2021-07-02 Ideaya Biosciences Inc Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
ES2942310T3 (es) * 2018-12-27 2023-05-31 Servier Lab Inhibidores aza-heterobicíclicos de MAT2A y métodos de uso para el tratamiento del cáncer
PE20212303A1 (es) * 2018-12-27 2021-12-10 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
WO2020243376A1 (en) * 2019-05-31 2020-12-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20230257359A1 (en) * 2020-06-10 2023-08-17 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20230257377A1 (en) * 2020-06-10 2023-08-17 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252678A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
TW202214630A (zh) * 2020-09-12 2022-04-16 大陸商成都倍特藥業股份有限公司 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2022143864A1 (zh) 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
CN115215862A (zh) * 2021-04-19 2022-10-21 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
JP2024540935A (ja) 2021-10-20 2024-11-06 インシリコ メディシン アイピー リミテッド メチオニンアデノシルトランスフェラーゼ２ａ（ｍａｔ２ａ）阻害剤およびその使用
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
EP4434989A4 (en) * 2021-12-21 2025-11-05 Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd Heterocyclic inhibitor of methionine adenosyltransferase 2A
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
IL314207A (en) * 2022-01-26 2024-09-01 Suzhou Genhouse Bio Co Ltd MAT2A inhibitor for the treatment of MTAP deletion type cancer
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
KR20250016234A (ko) 2022-06-27 2025-02-03 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 삼환 화합물 및 이의 용도
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AR130747A1 (es) 2022-10-13 2025-01-15 Hanmi Pharmaceutical Co Ltd Compuestos novedosos derivados de triciclo y usos de los mismos
WO2024183778A1 (zh) * 2023-03-06 2024-09-12 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
WO2024255805A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的晶型、其制备方法及用途
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064400A1 (en) 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
US20160115164A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
SG11201901747VA (en) * 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes

Also Published As

Publication number Publication date
AU2019243289B2 (en) 2023-01-12
WO2019191470A8 (en) 2019-12-12
AR115326A1 (es) 2020-12-23
WO2019191470A1 (en) 2019-10-03
SG11202009195WA (en) 2020-10-29
KR20200138769A (ko) 2020-12-10
US20210115045A1 (en) 2021-04-22
IL277665B2 (en) 2023-06-01
KR102736073B1 (ko) 2024-12-02
JP7350005B2 (ja) 2023-09-25
TW201946629A (zh) 2019-12-16
ES2973114T3 (es) 2024-06-18
PH12020551507A1 (en) 2021-09-13
UA127059C2 (uk) 2023-03-29
US11524960B2 (en) 2022-12-13
CN111936499B (zh) 2023-09-19
MA52232A (fr) 2021-02-17
BR112020020104A2 (pt) 2021-01-26
HUE066282T2 (hu) 2024-07-28
CA3094476A1 (en) 2019-10-03
EP3774805B1 (en) 2024-01-10
EA202092320A1 (ru) 2021-03-09
MX2020010005A (es) 2020-10-14
IL277665A (en) 2020-11-30
PL3774805T3 (pl) 2024-05-06
JP2023101762A (ja) 2023-07-21
EP3774805A1 (en) 2021-02-17
TWI719437B (zh) 2021-02-21
CN111936499A (zh) 2020-11-13
AU2019243289A1 (en) 2020-09-24
NZ767697A (en) 2025-02-28
JP2021519783A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
KR102823567B1 (ko) Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
EP3774805B1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP3902804A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
Chen et al. Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
WO2020243376A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2017019540A2 (en) Inhibitors of n-linked glycosylation and methods using same
RU2809987C2 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
EA046111B1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
BR112021012595B1 (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
HK40061678A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40061678B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
Faber Development of Allosteric Inhibitors Against Cyclin-Dependent Kinase 2 (CDK2)
OA20638A (en) Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer.
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220629

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240702

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250305

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250502

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250502

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250506

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260108